Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.61 USD
+0.21 (6.18%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.60 -0.01 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 341 - 360 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of FATE to ROTH Capital Research, due to the departure of the covering analyst, and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q17: ProTmune Safety Data in Mid-?17 and FATE-NK100 Clinical Data in 2H
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q, Executing Well on All Fronts: NK100 Program Expanding and ProTmune Safety Data Ahead, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of May 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q16: ProTmune and FATE-NK100 Promise a Lively 2017; Lowering PT to $6 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Conference 2017 Takeaways and 4Q16 Results; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q FY16, Fate Looks Compelling Ahead of Data-Rich Year, Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Adds to iPSC Technology, Expanded Platform Promising Immuno-oncology Play, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Presentations Showcase Versatility of Technology Platform
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q16: Rejigging the PROTECT Study May Have Long-term Payoff for ProTmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S